GlaxoSmithKline
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, GlaxoSmithKline sits in the top decile of US sponsors by registered trial count (#17 of 15,742 sponsors by registered trial count).
GlaxoSmithKline: 1,345 sponsored US clinical trials, 50 recruiting.
GlaxoSmithKline sponsors 1,345 registered US clinical trials on ClinicalTrials.gov, 50 of them currently recruiting, and 1,130 completed. 486 of these trials are in Phase 3-4 (later-stage) and 791 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pulmonary Disease, Chronic Obstructive, with 30 trials.
Top-decile sponsor footprint
GlaxoSmithKline ranks in the top decile of sponsors by registered trial count (#17 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,130 of 1,249 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,345 total, page 12 of 27
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus
NCT01627340
A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium
NCT01691482
Belimumab (BENLYSTA®) Pregnancy Registry
NCT01532310
Study to Evaluate Efficacy, Safety, and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A
NCT01610414
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age
NCT01621802
4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease
NCT01587924
Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children
NCT01545375
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic a Single Day of Dosing With GSK1614235.
NCT01607385
4 Week Correction Study in Subjects With Anemia Associated With Chronic Kidney Disease Who Are Not Undergoing Dialysis
NCT01587898
Effects of GSK1278863A on Pulmonary Artery Pressure in Healthy Volunteers
NCT01673555
Anti-caries Potential of a Sodium Monofluorophosphate and Calcium Sodium Phosphosilicate Dentifrice
NCT01657877
A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma
NCT01641692
Bioequivalence of RYTHMOL SR® Manufactured at Two Different Sites
NCT01956487
Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma
NCT01573624
A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease
NCT01494532
Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease
NCT01627327
Clinical Efficacy of a Toothpaste in Providing Relief From the Pain of Dentinal Hypersensitivity
NCT01592851
Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children
NCT01573767
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers
NCT01587703
A Dose-ranging Study of Fluticasone Furoate (FF)
NCT01563029
A Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers
NCT01702519
Effect of Fluoride in a Dentifrice on Remineralization of Erosive Lesions
NCT01641237
A Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy Subjects
NCT01648179
The Efficacy of a Dentifrice in Providing Relief From the Pain of Dentinal Hypersensitivity
NCT01592864
Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.
NCT01520909
A Clinical Study to Evaluate Experimental Children's Toothpastes in an In-Situ Caries Model
NCT01607411
Exploratory Efficacy Study of Guaifenesin in Upper Back Pain
NCT01562548
Gastrointestinal Safety Evaluation of Two Over the Counter Analgesics
NCT01822665
A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease
NCT01485172
An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be Assessed
NCT01583036
A Study to Evaluate Single and Repeat Doses of IV GSK2251052 in Healthy Male Japanese and Caucasian Subjects and Repeat Doses of Supratherapeutic Doses of IV GSK2251052 in Healthy Volunteers
NCT01495065
A Two Cohort Study to Look at the Metabolites of GSK221149, the Metabolism of GSK221149 Administered With a High Fat Meal and With Ketoconazole
NCT01627587
Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes
NCT01475734
A Study in Cancer Patients to Evaluate the Effect of Lapatinib on the QTc Interval
NCT01328054
Evaluation of Specific Biomarkers in Primary Invasive Breast Cancer
NCT01476111
Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl Metabolite
NCT01480609
SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.
NCT01475721
6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old
NCT01462344
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
NCT01536418
A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency
NCT01458067
A Study to Determine the Safety, Tolerability, and Effects of GSK2374697 in Healthy Volunteers
NCT01545570
Study of a New Thermo Stable Formulation of Epoprostenol Sodium to Treat Pulmonary Arterial Hypertension (PAH)
NCT01462565
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis
NCT01457924
Provoked Craving Relief Study by NRT
NCT01476202
A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis
NCT01395004
Evaluation of Efficacy of Experimental Gel to Foam Dentifrices in Dental Erosion
NCT01657903
An Adaptive Phase I Study to Evaluate the Safety, Efficacy and Dose Responses of Ronacaleret in Healthy Human Volunteers
NCT01466335
A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers
NCT01476137
A Clinical Study to Assess Two Doses of GSK2402968 in Subjects With Duchenne Muscular Dystrophy (DMD)
NCT01462292
GSK2251052 in the Treatment of Complicated Intra-abdominal Infections
NCT01381562
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 440 |
| Phase 2 | 351 |
| Phase 3 | 377 |
| Phase 4 | 109 |
Therapeutic Areas
What is open in the GlaxoSmithKline pipeline
50 recruiting of 1,345 indexed (4% open); 1,130 completed (84%).
Phase mix: 486 late (III/IV) vs 791 early (I/II) (early-phase heavy).
Top condition: Pulmonary Disease, Chronic Obstructive (30 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
GlaxoSmithKline: open-pipeline peers nationwide
Peers matched on 1,345 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
GlaxoSmithKline sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,345 trials (± recruiting share)
- Eli Lilly and Company · 1,341 trials · 9% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
- AstraZeneca · 1,285 trials · 12% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Stryker Orthopaedics · 4% recruiting · 27 trials
- US Oncology Research · 4% recruiting · 27 trials
- Otsuka Pharmaceutical Development & Commercialization · 4% recruiting · 221 trials
- Teva Branded Pharmaceutical Products R&D · 4% recruiting · 167 trials
Related
What to do with this GlaxoSmithKline page
1,345 registered trials is a research-attention snapshot, not an endorsement of GlaxoSmithKline or any single study.
- 50 of GlaxoSmithKline's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Pulmonary Disease, Chronic Obstructive is the condition GlaxoSmithKline studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pulmonary Disease, Chronic Obstructive trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. GlaxoSmithKline pipeline card: 1,345 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.